Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Titans Of Pharma 2024

How do big pharma CEO compensation packages stack up against company performance? 

Read More

Featured Stories


Avidity Is The Mid-Cap Rising Star Of 2024 So Far

New modalities and potential best-in-class challengers have excited investors in 2024 to date, but companies whose drugs have underperformed on the market have been punished.

Commercial Companies Launches

Narasimhan Playing The Long Game At Novartis

The head of the Basel-headquartered giant is no fan of bidding wars when it comes to dealmaking. "If we are outbid and it’s not within our envelope, we just walk away and we’re okay with that.”

Business Strategies Commercial Deals

Lucky No. 13? Artiva Goes Public, Rises In First Day Of Trading

Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

Financing Growth Immune Disorders

Asia Spotlight

Chiesi Takes Long View To Build Japan Rare Disease Presence

After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances. 

Japan Rare Diseases

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents

Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.

Deal Watch Business Strategies

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

Deal Watch Business Strategies

Executives On The Move: Abivax Aquires Chief Medical Officer From Landos Biopharma And Gets a New Chief Strategy Officer

Recent moves in the industry include C-suite shuffles at AbbVie, Abivax and Ikena Oncology, plus I-Mab.

Leadership Executive Changes

Finance Watch: NGM Reemerges With $122m During Post-July 4th VC Mega-Round Boom

Private Company Edition: After its acquisition by an investor earlier this year, NGM Bio has raised a $122m series A round, adding to a recent surge in large venture capital financings. Also, Vanqua Bio disclosed $45m in new funding and Renalys completed a $38.4m series A.

Financing Growth
Interviews

CAR-T To N-of-1 Studies: How Jeeva Is Helping Drive Trial Efficiencies

Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for numerous point solutions and vendors, enabling sponsors to undertake trials more effectively including in the complex and competitive oncology space.

Clinical Trials Research & Development

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

Financing Cardiovascular

ASCO Data Are Catalyst For CatalYm Cash Boost

The German biotech has unveiled a $150m series D financing round to support a “broad Phase IIb development program for visugromab” and explore its potential to induce cancer remission depth and durability across multiple solid tumor indications.

Financing ImmunoOncology

IGBA’s Almeida On Patent Quality, Single Data Package Globally For Off-Patent Drugs

IGBA's secretary general, in an interview with Scrip, bolsters the case for enabling single global development of off-patent medicines and the acceptance of foreign comparators in bioequivalence studies as complex and niche therapeutics increasingly dot pharma’s pipeline. The global off-patent industry association, she maintained, is also “paying attention” to patent quality in various regions.

Policy Regulation
See All
Graphics

Obesity Rules Large-Cap Stocks In First Half Of 2024

Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.

Business Strategies Companies

The IPO Queue Fills Up, But A Recovery Is A Way Off

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Financing Commercial

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A

Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts

Keytruda enjoyed its fifth consecutive quarter as the world’s top-selling drug in the first three months of 2024. As Comirnaty and Spikevax fell out of the list, Vertex’s cystic fibrosis pill Trikafta/Kaftrio became one of the top 10 best-selling drugs for the first time.

Sales & Earnings Commercial
See All
Recent Stories

AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds

A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.

Artificial Intelligence Business Strategies

Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents

Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.

Deal Watch Business Strategies

Chiesi Takes Long View To Build Japan Rare Disease Presence

After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances. 

Japan Rare Diseases

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.

Deal Watch Business Strategies

Phathom Voquezna Expansion Strategy Poised To Deliver In GERD

The acid reducer was approved by the US FDA for a substantially larger indication in non-erosive gastroesophageal reflux disease but will have to prove itself commercially against PPIs.

Approvals Launches

FDA Leaves Door Open For Further Discussions With Agenus Over BOT/BAL

The biotech company surprised observers when it announced the agency advised against filing for accelerated approval of the CTLA-4/PD-1 combination.

FDA Business Strategies

Roche On Track To Supplement Relaunched Susvimo’s Label

Having relaunched Susvimo for wet AMD, Roche now has the ocular implant under FDA review for approval in two diabetic ophthalmic indications and presented two-year data in those settings.

Clinical Trials Drug Approval Standards

Cosentyx Delivers Again For Novartis With Hidradenitis Suppurativa Launch

Two older drugs – Cosentyx and Entresto – continue to drive growth at the Swiss giant, while Leqvio is finally making its mark on the sales front.

Sales & Earnings Business Strategies

Boehringer Looks To Revitalise Its Pipeline

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.

Sales & Earnings Companies

Executives On The Move: Abivax Aquires Chief Medical Officer From Landos Biopharma And Gets a New Chief Strategy Officer

Recent moves in the industry include C-suite shuffles at AbbVie, Abivax and Ikena Oncology, plus I-Mab.

Leadership Executive Changes

China’s Public Payer Challenged To Support Domestic Innovative Drug Market

One Chinese biotech executive is entertaining hopes of China’s domestic market for novel drugs growing to CNY300bn ($41bn). However, the country’s public payer spent just CNY90bn on such products in 2023 and is expected to increase expenditure to more than CNY100bn this year.

China Reimbursement

SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal

After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.

Deals Cancer
UsernamePublicRestriction

Register